Status:
COMPLETED
Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy
Lead Sponsor:
University of Oklahoma
Conditions:
Hemoptysis
Eligibility:
All Genders
18-80 years
Brief Summary
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals wi...
Detailed Description
This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the le...
Eligibility Criteria
Inclusion
- Any patient scheduled to undergo bronchoscopy
Exclusion
- Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000
- Patients not scheduled to undergo bronchoalveolar lavage (BAL)
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00929565
Start Date
June 1 2009
End Date
October 1 2011
Last Update
April 9 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Medical Center
Oklahoma City, Oklahoma, United States, 73104